Jennison Associates LLC lowered its stake in shares of Humana Inc. (NYSE:HUM) by 0.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 407,364 shares of the insurance provider’s stock after selling 2,677 shares during the quarter. Jennison Associates LLC owned about 0.28% of Humana worth $99,246,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of the stock. Advantus Capital Management Inc grew its position in Humana by 1.4% during the third quarter. Advantus Capital Management Inc now owns 14,798 shares of the insurance provider’s stock worth $3,605,000 after buying an additional 203 shares in the last quarter. Bank of Hawaii grew its position in Humana by 61.8% during the third quarter. Bank of Hawaii now owns 2,984 shares of the insurance provider’s stock worth $727,000 after buying an additional 1,140 shares in the last quarter. Principal Financial Group Inc. grew its position in Humana by 10.5% during the third quarter. Principal Financial Group Inc. now owns 386,776 shares of the insurance provider’s stock worth $94,230,000 after buying an additional 36,899 shares in the last quarter. Pettee Investors Inc. acquired a new stake in Humana during the third quarter worth approximately $207,000. Finally, Harvest Management LLC acquired a new stake in Humana during the third quarter worth approximately $292,000. 95.88% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Jennison Associates LLC Has $99.25 Million Position in Humana Inc. (HUM)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2017/11/12/jennison-associates-llc-has-99-25-million-position-in-humana-inc-hum.html.
In other news, VP Timothy S. Huval sold 7,803 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $258.14, for a total value of $2,014,266.42. Following the completion of the sale, the vice president now directly owns 8,831 shares in the company, valued at approximately $2,279,634.34. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider William Kevin Fleming sold 3,071 shares of Humana stock in a transaction dated Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total value of $770,759.58. Following the transaction, the insider now owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,660 shares of company stock valued at $5,319,600. 0.80% of the stock is currently owned by company insiders.
A number of equities research analysts have weighed in on HUM shares. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Credit Suisse Group started coverage on Humana in a report on Thursday, November 2nd. They issued a “neutral” rating and a $256.00 target price on the stock. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. UBS AG reaffirmed a “neutral” rating and issued a $250.00 target price (up previously from $237.00) on shares of Humana in a report on Wednesday, August 9th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $223.00 target price (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Thirteen investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $252.81.
Shares of Humana Inc. (HUM) traded down $3.07 on Friday, hitting $244.39. The stock had a trading volume of 1,265,400 shares, compared to its average volume of 1,118,081. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.65 and a current ratio of 1.61. The firm has a market cap of $34,913.55, a P/E ratio of 20.85, a PEG ratio of 1.58 and a beta of 0.91. Humana Inc. has a 12 month low of $186.25 and a 12 month high of $264.56.
Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.27 by $0.12. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The firm’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period last year, the business posted $3.18 EPS. equities research analysts predict that Humana Inc. will post 11.64 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.65%. Humana’s dividend payout ratio is presently 12.59%.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM).
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.